News Details

Manila, March 2026. The Philippines has notified a draft FDA Circular that would introduce detailed requirements on the maintenance of importation and distribution records, as well as the reporting of product complaints, adverse events, and field safety corrective actions for medical devices. The proposal forms part of a broader effort to strengthen post-market surveillance and improve traceability and regulatory response across the medical device lifecycle.

Relevant background and regulatory context

The draft Circular is grounded in the Philippines’ existing legal framework under Republic Act No. 3720, as amended, and Republic Act No. 9711, which mandate the Food and Drug Administration to ensure the safety, quality, and performance of health products. It also builds on Administrative Order No. 2018-0002 and aligns with the ASEAN Medical Device Directive, particularly Annex 5 on the Post-Marketing Alert System.

The Circular is also positioned alongside more recent national efforts to operationalize post-market alert system requirements under ASEAN harmonization initiatives, indicating a continued shift toward regionally aligned medical device regulation.

What the draft regulation does

The draft establishes a comprehensive framework covering four core post-market surveillance components.

First, it introduces standardized requirements for maintaining importation and distribution records to ensure traceability across the supply chain.

Second, it defines processes for handling and documenting product complaints.

Third, it sets criteria, timelines, and procedures for reporting adverse events.

Fourth, it establishes requirements for initiating, reporting, and closing field safety corrective actions.

Together, these elements aim to create a more structured and consistent post-market monitoring system for medical devices placed on the Philippine market.

Scope and applicability

The Circular applies to all registered medical devices and in vitro diagnostic medical devices distributed in the Philippines. It covers all relevant actors in the supply chain, including manufacturers, importers, distributors, wholesalers, retailers, and marketing authorization holders.

However, certain post-market activities, such as product recalls and issues involving unauthorized medical devices, remain governed by separate regulatory instruments.

Traceability and record-keeping requirements

A central feature of the proposal is the strengthening of traceability obligations.

Marketing Authorization Holders would be required to maintain importation and distribution records up to the initial consignee, while dealers must maintain records up to the end-user. These records must include key data points such as consignee details, product identification, quantities, dates of distribution, batch or serial numbers, and supporting documentation such as invoices and delivery receipts.

Record retention requirements are also specified. Records must generally be kept for the duration of the product’s useful life or shelf life, or at least two years after supply, whichever is longer. This is intended to ensure that products can be effectively traced and withdrawn if safety concerns arise.

Product complaint handling framework

The draft introduces clearer obligations for complaint management.

Dealers are required to forward complaints to the Marketing Authorization Holder within 14 calendar days. The Marketing Authorization Holder must then assess whether the complaint meets the criteria for a reportable adverse event or field safety corrective action.

All valid complaints must be documented, including investigation outcomes and corrective or preventive measures. Complaint records must be retained for extended periods, generally five years beyond the product’s useful life or shelf life, reflecting the importance of long-term monitoring of device performance.

Adverse event reporting: criteria and timelines

The Circular defines specific criteria for what constitutes a reportable adverse event, focusing on events that result in or could lead to serious health consequences, including death, serious injury, or significant public health risks.

It also introduces clear reporting timelines.

Events posing a serious public health threat must be reported within 48 hours. Events involving death or serious deterioration in health must be reported within 10 calendar days. Events that could potentially lead to serious harm if they recur must be reported within 30 calendar days.

The proposal also requires follow-up and final reporting, ensuring that initial notifications are supplemented with complete investigations and risk assessments.

Field safety corrective actions become more structured

The draft provides detailed procedures for field safety corrective actions.

Marketing Authorization Holders must determine the need for such actions based on risk assessments and post-market surveillance data. Once initiated, field safety corrective actions must be reported within 14 calendar days.

The Circular also outlines requirements for final reporting and closure. A corrective action is considered closed only after the FDA confirms that all necessary measures have been implemented and verified. This formalizes regulatory oversight of risk mitigation actions taken in the field.

Alignment with ASEAN and international practices

The draft explicitly aligns with the ASEAN Medical Device Directive, particularly the Post-Marketing Alert System under Annex 5. This reflects the Philippines’ ongoing efforts to harmonize its regulatory system with regional and international best practices, including standardized reporting formats and timelines.

Transitional arrangements and entry into force

The Circular provides a six-month transition period from its effective date to allow Marketing Authorization Holders and other stakeholders to align their systems and procedures with the new requirements.

The proposed entry into force is 15 days after publication in the Official Gazette or a national newspaper of general circulation, although adoption is still pending and subject to the outcome of the consultation process.

Business implications

For companies operating in the Philippine medical device market, the draft introduces more stringent and clearly defined post-market obligations. Businesses will need to ensure robust internal systems for traceability, complaint management, adverse event monitoring, and corrective action implementation.

The increased specificity around reporting timelines, documentation, and regulatory follow-up is likely to require updates to quality management systems, internal procedures, and coordination across supply chain partners.

Overall, the proposal signals a shift toward a more proactive and data-driven post-market surveillance regime, with stronger accountability for all actors involved in placing medical devices on the market.